Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) - Share price


Stock Report

Alnylam Pharmaceuticals Inc ALNY

Last Price
$75.37

Day Change
-0.52|-0.69%

As of 19/07/2019
17:11:36 EDT | USD
Minimum 15 Minutes Delay.

Last Close75.89
Day Range74.75 - 75.95
Mkt Cap8.03Bil
52-Wk Range60.27 - 124.22
Yield %-
ISINUS02043Q1076
Volume1,334,910
P/E-9.55
P/S89.29
P/CF-12.90

Share Price

Financials
201620172018
More ...
Income Statement
Revenue47.1689.9174.91
Operating Income-424.59-500.09-814.67
Net Income-410.11-490.87-761.50
Basic EPS-4.79-5.42-7.57
Avg. Diluted Shares Outstanding8691101
Balance Sheet
Current Assets671.881,764.741,200.70
Non Current Assets590.93229.99374.11
Total Assets1,262.811,994.731,574.80
Current Liabilities131.70144.25179.49
Total Liabilities342.59228.30272.84
Total Equity920.221,766.431,301.97
Cash Flow
Operating Cash Flow-307.70-382.79-562.62
Capital Expenditure-64.56-104.21-126.89
Free Cash Flow-372.26-487.00-689.50

In millions, except "Basic EPS". Currency is USD.

Company Profile

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Mid-Growth

Fiscal Year Ends

December

Employees

1,065
Key Stats
More ...
Price/Earning TTM-9.62
Price/Book5.23
Price/Sales TTM89.64
Rev Growth (3 year avg)22.15
EPS Growth (3 year avg)-
Operating Margin % TTM-1,087.56
Net Margin % TTM-1,016.58
ROE TTM-49.63
Debt/Equity0.02
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.